ClinicalTrials.gg
CompletedNCT02688088Updated Oct 18, 2022Results posted

A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body

A Phase 1 interventional study of Drug Cocktail and Abemaciclib in Neoplasm Metastasis, sponsored by Eli Lilly and Company. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-18.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 72 studies in Neoplasm Metastasis by Eli Lilly and Company — 7 open to participants now, 16 under way, 7 of them phase 3. Neoplasm Metastasis · Eli Lilly and Company.

Enrollment
43rd of 66
48 · median 77
Started
2016
with 5 others
Phase 1
43 of 72
3 open now
Registered
48th of 72
by date

Among the 72 studies in Neoplasm Metastasis by Eli Lilly and Company, this one is the 43rd largest by enrollment of the 66 interventional ones that give a count, is one of 6 that started in 2016, is one of 43 in phase 1, and was the 48th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

7 of the 72 studies in Neoplasm Metastasis by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Neoplasm Metastasis by Eli Lilly and Company, or all of them as a file.
02

Study summary

This study is known as a "drug interaction study" and is being done to see how abemaciclib may affect the blood levels of a drug mixture of commonly used drugs (caffeine, warfarin, dextromethorphan, and midazolam) when taken in combination with abemaciclib. Each participant will complete screening and four study periods in a fixed sequence, with the option to continue to receive abemaciclib in a safety extension phase. All participants will complete a safety follow-up.

03

Conditions studied

  • Neoplasm Metastasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have histological or cytological evidence of a diagnosis of cancer that is advanced and/or
  • Have adequate organ function
  • Have a performance status of ≤2 on the (ECOG) scale
  • Have discontinued all previous therapies for cancer (including chemotherapy, radiotherapy, immunotherapy, cancer-related hormone therapy, and therapy) for at least 21 days for myelosuppressive agents or 14 days for nonmyelosuppressive agents prior to receiving study drug and have recovered from the acute effects of therapy(treatment related toxicity resolved to baseline), except for residual alopecia

Exclusion criteria

Exclusion Criteria:

  • Require treatment with inducers or inhibitors of cytochrome P450 (CYP)1A2, CYP2C9, CYP2D6, and within 14 days before the first dose of study drug through the end of Period 2
  • History or presence of significant bleeding disorders
  • Have known active uncontrolled or symptomatic
  • Have a primary liver tumor
  • Have lymphoma or leukemia
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Active comparator
    Drug Cocktail - Period 1

    Single dose of drug cocktail: 100 milligram (mg) caffeine,10 mg warfarin, 30 mg dextromethorphan, and 0.2 mg midazolam administered orally on Day 1 in Period 1.

    Drug: Drug Cocktail

  • Experimental
    200 mg Abemaciclib + Drug Cocktail - Period 2

    200 mg Abemaciclib administered orally every 12 hours (Q12H) on Days 1 - 12 in Period 2 with a single dose of drug cocktail: 100 mgcaffeine,10 mg warfarin, 30 mg dextromethorphan, and 0.2 mg midazolam administered orally on Day 8 in Period 2.

    Drug: Drug Cocktail · Drug: Abemaciclib

  • Experimental
    200 mg Abemaciclib - Period 3

    200 mg Abemaciclib administered orally Q12H on Days 13 to 28 in Period 3. Participants may continue to receive abemaciclib until discontinuation criteria are met.

    Drug: Abemaciclib

  • Experimental
    200 mg Abemaciclib - Period 4

    200 mg Abemaciclib administered orally Q12H on Days 1 to 28 in Period 4. Participants may continue to receive abemaciclib until discontinuation criteria are met.

    Drug: Abemaciclib

  • Experimental
    Safety Extension Period

    200 mg Abemaciclib administered orally Q12H on Days 1 to 28 onwards in extension period. Participants may continue to receive abemaciclib until discontinuation criteria are met.

    Drug: Abemaciclib

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics: Maximum Concentration (Cmax) of Caffeine

    Maximum concentration of caffeine after single dose of drug cocktail on Day 1 in Period 1 and in combination with Abemaciclib on Day 8 in Period 2.

    Time frame: Days 1 and 8: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, and 48 hours (hr) Postdose

  2. Pharmacokinetics: Maximum Concentration (Cmax) S-Warfarin

    Maximum concentration of S-warfarin after single dose of drug cocktail on Day 1 in Period 1and in combination with Abemaciclib on Day 8 in Period 2.

    Time frame: Days 1 and 8: Predose, 0.5 1, 2, 3, 4, 6, 8, 12, 48, 72, 96 hr Postdose

  3. Pharmacokinetics: Maximum Concentration (Cmax) of Dextromethorphan

    Maximum concentration of dextromethorphan after single dose of drug cocktail on Day 1 of Period 1 and in combination with Abemaciclib on Day 8 in Period 2.

    Time frame: Days 1 and 8: Predose, 1, 2, 4, 6, 8, 10, 24, 48, 72 hr postdose

  4. Pharmacokinetics: Maximum Concentration (Cmax) of Midazolam

    Maximum concentration of midazolam after single dose of drug cocktail on Day 1 of Period 1 and in combination with Abemaciclib on Day 8 in Period 2.

    Time frame: Days 1 and 8: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hr Postdose

  5. Pharmacokinetics: Area Under the Concentration Versus Time Curve [AUC(0-infinity)] of Caffeine

    PK: AUC zero to infinity of caffeine after single dose of drug cocktail on Day 1 in Period 1 and in combination with Abemaciclib on Day 8 in Period 2.

    Time frame: Days 1 and 8: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48 hr Postdose

  6. Pharmacokinetics: Area Under the Concentration Versus Time Curve [AUC(0-infinity)] of S-Warfarin

    AUC (zero to infinity) of S-warfarin after single dose of drug cocktail on Day 1 in Period 1 and in combination with Abemaciclib on Day 8 in Period 2.

    Time frame: Days 1 and 8: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hr Postdose

  7. Pharmacokinetics: Area Under the Concentration Versus Time Curve [AUC(0-infinity)] of Dextromethorphan

    PK: AUC (zero to infinity) of dextromethorphan after single dose of drug cocktail on Day 1 in Period 1 and in combination with Abemaciclib on Day 8 in Period 2.

    Time frame: Days 1 and 8: 1, 2, 4, 6, 8, 10, 24, 48, 72 hr Postdose

  8. Pharmacokinetics: Area Under the Concentration Versus Time Curve [AUC(0-infinity)] of Midazolam

    PK: AUC (zero to infinity) of midazolam after single dose of drug cocktail on Day 1 in Period 1 and in combination with Abemaciclib on Day 8 in Period 2.

    Time frame: Days 1 and 8: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hr Postdose

Secondary outcomes

  1. Mean Change From Baseline at 24 Hours in Systolic and Diastolic Blood Pressure in Period 1

    Mean change from predose in systolic and diastolic blood pressure (BP) over 24 hours (h) postdose following single dose drug cocktail in Period 1.

    Time frame: Day 8: Baseline, 24 h postdose

  2. Mean Change From Baseline at 24 Hours in Pulse Rate in Period 1

    Mean change from baseline in pulse rate over 24 hours (h) postdose following single dose drug cocktail in Period 1.

    Time frame: Day 8: Baseline, 24 h postdose

  3. Mean Change From Baseline at 24 Hours in Systolic and Diastolic Blood Pressure in Period 2

    Mean change from baseline in systolic and diastolic blood pressure (BP) over 24 hours (h) postdose following single dose of abemaciclib in Period 2, Day 1.

    Time frame: Day 1: Baseline, 24 h postdose

  4. Mean Change From Baseline at 24 Hours in Pulse Rate in Period 2

    Mean change from baseline in pulse rate over 24 hours (h) postdose following single dose drug cocktail in Period 2, Day 1.

    Time frame: Day 1: Baseline, 24 h postdose

  5. Mean Change From Baseline at 24 Hours in Systolic and Diastolic Blood Pressure in Period 2

    Mean change from baseline in systolic and diastolic blood pressure (BP) at 24 h postdose following 200 mg abemaciclib and drug cocktail.

    Time frame: Day 8: Baseline, 24 h postdose

  6. Mean Change From Baseline at 24 Hours in Pulse Rate in Period 2

    Mean change from baseline in pulse rate at 24 h postdose following 200 mg abemaciclib and drug cocktail.

    Time frame: Day 8: Baseline, 24 h postdose

07

Results

Posted Oct 18, 2022

Participant flow

Abemaciclib dose adjustments were allowed due to drug-related toxicity. Before the start of each cycle, drug-related toxicities must have resolved to either baseline or at least Grade 2. Participants not recovered from toxicities within 14 days were discontinued from the study. For Period 2, if abemaciclib dose adjustments occurred, dosing with the drug cocktail was permitted to be delayed to allow for adequate exposure.

Single Dose Drug Cocktail - Period 1
Participant flow — Single Dose Drug Cocktail - Period 1
MilestoneDrug Cocktail - Period 1200 mg Abemaciclib + Drug Cocktail - Period 2200 mg Abemaciclib - Period 3200 mg Abemaciclib Period - 4Abemaciclib Safety Extension Period
Started440000
Received one dose of drug cocktail440000
Completed440000
Not completed00000
Abemaciclib + Drug Cocktail - Period 2
Participant flow — Abemaciclib + Drug Cocktail - Period 2
MilestoneDrug Cocktail - Period 1200 mg Abemaciclib + Drug Cocktail - Period 2200 mg Abemaciclib - Period 3200 mg Abemaciclib Period - 4Abemaciclib Safety Extension Period
Started044000
Received at least one dose of study drug042000
Completed037000
Not completed07000
Withdrew: Adverse event01000
Withdrew: Death01000
Withdrew: Withdrawal by subject03000
Withdrew: Physician decision02000
Abemaciclib Days 13 to 28 - Period 3
Participant flow — Abemaciclib Days 13 to 28 - Period 3
MilestoneDrug Cocktail - Period 1200 mg Abemaciclib + Drug Cocktail - Period 2200 mg Abemaciclib - Period 3200 mg Abemaciclib Period - 4Abemaciclib Safety Extension Period
Started003700
Received at least one dose of study drug003600
Completed002900
Not completed00800
Withdrew: Physician decision00700
Withdrew: Withdrawal by subject00100
Abemaciclib Days 1 to 28 - Period 4
Participant flow — Abemaciclib Days 1 to 28 - Period 4
MilestoneDrug Cocktail - Period 1200 mg Abemaciclib + Drug Cocktail - Period 2200 mg Abemaciclib - Period 3200 mg Abemaciclib Period - 4Abemaciclib Safety Extension Period
Started000290
Completed000210
Not completed00080
Withdrew: Physician decision00070
Withdrew: Withdrawal by subject00010
Abemaciclib Safety Extension Period
Participant flow — Abemaciclib Safety Extension Period
MilestoneDrug Cocktail - Period 1200 mg Abemaciclib + Drug Cocktail - Period 2200 mg Abemaciclib - Period 3200 mg Abemaciclib Period - 4Abemaciclib Safety Extension Period
Started000018
Received at least one dose of study drug000018
Completed00000
Not completed000018
Withdrew: Met discontinuation criteria000018

Outcome measures

PrimaryPharmacokinetics: Maximum Concentration (Cmax) of Caffeine

Maximum concentration of caffeine after single dose of drug cocktail on Day 1 in Period 1 and in combination with Abemaciclib on Day 8 in Period 2.

Time frame:
Days 1 and 8: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, and 48 hours (hr) Postdose
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Pharmacokinetics: Maximum Concentration (Cmax) of Caffeine
nanograms per milliliter (ng/mL)100 mg CaffeineAbemaciclib + 100 mg Caffeine
Pharmacokinetics: Maximum Concentration (Cmax) of Caffeine2890 ± 292950 ± 33
Statistical analysis
  • 100 mg Caffeine vs Abemaciclib + 100 mg Caffeine · Ratio of geometric ls means: 1.01 · 90% CI 0.965 to 1.06
PrimaryPharmacokinetics: Maximum Concentration (Cmax) S-Warfarin

Maximum concentration of S-warfarin after single dose of drug cocktail on Day 1 in Period 1and in combination with Abemaciclib on Day 8 in Period 2.

Time frame:
Days 1 and 8: Predose, 0.5 1, 2, 3, 4, 6, 8, 12, 48, 72, 96 hr Postdose
Reported as:
Geometric mean · ng/mL
Pharmacokinetics: Maximum Concentration (Cmax) S-Warfarin
ng/mL10 mg Warfarin200 mg Abemaciclib + 10 mg Warfarin
Pharmacokinetics: Maximum Concentration (Cmax) S-Warfarin561 ± 35526 ± 35
Statistical analysis
  • 10 mg Warfarin vs 200 mg Abemaciclib + 10 mg Warfarin · Ratio of geometric ls means: 0.935 · 90% CI 0.871 to 1.00
PrimaryPharmacokinetics: Maximum Concentration (Cmax) of Dextromethorphan

Maximum concentration of dextromethorphan after single dose of drug cocktail on Day 1 of Period 1 and in combination with Abemaciclib on Day 8 in Period 2.

Time frame:
Days 1 and 8: Predose, 1, 2, 4, 6, 8, 10, 24, 48, 72 hr postdose
Reported as:
Geometric mean · ng/mL
Pharmacokinetics: Maximum Concentration (Cmax) of Dextromethorphan
ng/mL30 mg Dextromethorphan200 Abemaciclib + 30 mg Dextromethorphan
Pharmacokinetics: Maximum Concentration (Cmax) of Dextromethorphan3.18 ± 1823.30 ± 164
Statistical analysis
  • 30 mg Dextromethorphan vs 200 Abemaciclib + 30 mg Dextromethorphan · Ratio of geometric ls means: 1.05 · 90% CI 0.898 to 1.22
PrimaryPharmacokinetics: Maximum Concentration (Cmax) of Midazolam

Maximum concentration of midazolam after single dose of drug cocktail on Day 1 of Period 1 and in combination with Abemaciclib on Day 8 in Period 2.

Time frame:
Days 1 and 8: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hr Postdose
Reported as:
Geometric mean · ng/mL
Pharmacokinetics: Maximum Concentration (Cmax) of Midazolam
ng/mL0.2 mg Midazolam (Drug Cocktail)200 mg Abemaciclib + 0.2 mg Midazolam
Pharmacokinetics: Maximum Concentration (Cmax) of Midazolam2.12 ± 541.75 ± 48
Statistical analysis
  • 0.2 mg Midazolam (Drug Cocktail) vs 200 mg Abemaciclib + 0.2 mg Midazolam · Ratio of geometric ls means: 0.845 · 90% CI 0.760 to 0.940
PrimaryPharmacokinetics: Area Under the Concentration Versus Time Curve [AUC(0-infinity)] of Caffeine

PK: AUC zero to infinity of caffeine after single dose of drug cocktail on Day 1 in Period 1 and in combination with Abemaciclib on Day 8 in Period 2.

Time frame:
Days 1 and 8: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48 hr Postdose
Reported as:
Geometric least squares mean · nanograms*hour per milliliter (ng*h/mL)
Pharmacokinetics: Area Under the Concentration Versus Time Curve [AUC(0-infinity)] of Caffeine
nanograms*hour per milliliter (ng*h/mL)100 mg Caffeine200 mg Abemaciclib + 100 mg Caffeine
Pharmacokinetics: Area Under the Concentration Versus Time Curve [AUC(0-infinity)] of Caffeine32500 ± 7247100 ± 89
Statistical analysis
  • 100 mg Caffeine vs 200 mg Abemaciclib + 100 mg Caffeine · Ratio of geometric ls means: 1.56 · 90% CI 1.35 to 1.81
PrimaryPharmacokinetics: Area Under the Concentration Versus Time Curve [AUC(0-infinity)] of S-Warfarin

AUC (zero to infinity) of S-warfarin after single dose of drug cocktail on Day 1 in Period 1 and in combination with Abemaciclib on Day 8 in Period 2.

Time frame:
Days 1 and 8: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hr Postdose
Reported as:
Geometric mean · ng*h/mL
Pharmacokinetics: Area Under the Concentration Versus Time Curve [AUC(0-infinity)] of S-Warfarin
ng*h/mL10 mg Warfarin200 mg Abemaciclib + 10 mg Warfarin
Pharmacokinetics: Area Under the Concentration Versus Time Curve [AUC(0-infinity)] of S-Warfarin21400 ± 4320600 ± 40
Statistical analysis
  • 10 mg Warfarin vs 200 mg Abemaciclib + 10 mg Warfarin · Ratio of geometric ls means: 1.04 · 90% CI 0.956 to 1.13
PrimaryPharmacokinetics: Area Under the Concentration Versus Time Curve [AUC(0-infinity)] of Dextromethorphan

PK: AUC (zero to infinity) of dextromethorphan after single dose of drug cocktail on Day 1 in Period 1 and in combination with Abemaciclib on Day 8 in Period 2.

Time frame:
Days 1 and 8: 1, 2, 4, 6, 8, 10, 24, 48, 72 hr Postdose
Reported as:
Geometric mean · ng*h/mL
Pharmacokinetics: Area Under the Concentration Versus Time Curve [AUC(0-infinity)] of Dextromethorphan
ng*h/mL30 mg Dextromethorphan200 mg Abemaciclib + 30 mg Dextromethorphan
Pharmacokinetics: Area Under the Concentration Versus Time Curve [AUC(0-infinity)] of Dextromethorphan32.6 ± 31632.1 ± 238
Statistical analysis
  • 30 mg Dextromethorphan vs 200 mg Abemaciclib + 30 mg Dextromethorphan · Mean difference (final values): 0.976 · 90% CI 0.805 to 1.18
PrimaryPharmacokinetics: Area Under the Concentration Versus Time Curve [AUC(0-infinity)] of Midazolam

PK: AUC (zero to infinity) of midazolam after single dose of drug cocktail on Day 1 in Period 1 and in combination with Abemaciclib on Day 8 in Period 2.

Time frame:
Days 1 and 8: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hr Postdose
Reported as:
Geometric mean · ng*h/mL
Pharmacokinetics: Area Under the Concentration Versus Time Curve [AUC(0-infinity)] of Midazolam
ng*h/mL0.2 mg Midazolam200 mg Abemaciclib + 0.2 mg Midazolam
Pharmacokinetics: Area Under the Concentration Versus Time Curve [AUC(0-infinity)] of Midazolam7.34 ± 746.03 ± 63
Statistical analysis
  • 0.2 mg Midazolam vs 200 mg Abemaciclib + 0.2 mg Midazolam · Ratio of geometric ls means: 0.867 · 90% CI 0.775 to 0.972
SecondaryMean Change From Baseline at 24 Hours in Systolic and Diastolic Blood Pressure in Period 1

Mean change from predose in systolic and diastolic blood pressure (BP) over 24 hours (h) postdose following single dose drug cocktail in Period 1.

Time frame:
Day 8: Baseline, 24 h postdose
Reported as:
Mean · millimeter of mercury (mmHg)
Mean Change From Baseline at 24 Hours in Systolic and Diastolic Blood Pressure in Period 1
millimeter of mercury (mmHg)Drug Cocktail Period 1
Systolic BP-2.5 ± 13.9
Diastolic BP-0.7 ± 10.1
SecondaryMean Change From Baseline at 24 Hours in Pulse Rate in Period 1

Mean change from baseline in pulse rate over 24 hours (h) postdose following single dose drug cocktail in Period 1.

Time frame:
Day 8: Baseline, 24 h postdose
Reported as:
Mean · Beats per minute (bpm)
Mean Change From Baseline at 24 Hours in Pulse Rate in Period 1
Beats per minute (bpm)Drug Cocktail Period 1
Mean Change From Baseline at 24 Hours in Pulse Rate in Period 1-1.3 ± 11.1
SecondaryMean Change From Baseline at 24 Hours in Systolic and Diastolic Blood Pressure in Period 2

Mean change from baseline in systolic and diastolic blood pressure (BP) over 24 hours (h) postdose following single dose of abemaciclib in Period 2, Day 1.

Time frame:
Day 1: Baseline, 24 h postdose
Reported as:
Mean · mmHg
Mean Change From Baseline at 24 Hours in Systolic and Diastolic Blood Pressure in Period 2
mmHg200 mg Abemaciclib
Systolic BP-7.8 ± 15.2
Diastolic BP-1.8 ± 10.4
SecondaryMean Change From Baseline at 24 Hours in Pulse Rate in Period 2

Mean change from baseline in pulse rate over 24 hours (h) postdose following single dose drug cocktail in Period 2, Day 1.

Time frame:
Day 1: Baseline, 24 h postdose
Reported as:
Mean · bpm
Mean Change From Baseline at 24 Hours in Pulse Rate in Period 2
bpm200 mg Abemaciclib
Mean Change From Baseline at 24 Hours in Pulse Rate in Period 2-0.2 ± 12.5
SecondaryMean Change From Baseline at 24 Hours in Systolic and Diastolic Blood Pressure in Period 2

Mean change from baseline in systolic and diastolic blood pressure (BP) at 24 h postdose following 200 mg abemaciclib and drug cocktail.

Time frame:
Day 8: Baseline, 24 h postdose
Reported as:
Mean · mmHg
Mean Change From Baseline at 24 Hours in Systolic and Diastolic Blood Pressure in Period 2
mmHg200 mg Abemaciclib + Drug Cocktail
Systolic BP-11.6 ± 16.8
Diastolic BP-6.1 ± 10.5
SecondaryMean Change From Baseline at 24 Hours in Pulse Rate in Period 2

Mean change from baseline in pulse rate at 24 h postdose following 200 mg abemaciclib and drug cocktail.

Time frame:
Day 8: Baseline, 24 h postdose
Reported as:
Mean · bpm
Mean Change From Baseline at 24 Hours in Pulse Rate in Period 2
bpm200 mg Abemaciclib + Drug Cocktail
Mean Change From Baseline at 24 Hours in Pulse Rate in Period 24.1 ± 14.9

Adverse events

Collected over Baseline up to 46 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Drug Cocktail - Period 11/44 (2.3%)1/44 (2.3%)22/44 (50%)
200 mg Abemaciclib - Period 20/42 (0%)3/42 (7.1%)33/42 (78.6%)
200 mg Abemaciclib + Drug Cocktail - Period 20/35 (0%)2/35 (5.7%)26/35 (74.3%)
200 mg Abemaciclib - Periods 3 and 40/28 (0%)6/28 (21.4%)25/28 (89.3%)
Abemaciclib Safety Extension Period0/18 (0%)2/18 (11.1%)16/18 (88.9%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventDrug Cocktail - Period 1200 mg Abemaciclib - Period 2200 mg Abemaciclib + Drug Cocktail - Period 2200 mg Abemaciclib - Periods 3 and 4Abemaciclib Safety Extension Period
ColitisGastrointestinal disorders0/440/420/350/281/18
OesophagitisGastrointestinal disorders0/440/420/350/281/18
PancreatitisGastrointestinal disorders0/440/420/350/281/18
Clostridium difficile colitisInfections and infestations0/440/420/350/281/18
DiverticulitisInfections and infestations0/440/420/350/281/18
DyspnoeaRespiratory, thoracic and mediastinal disorders0/440/420/350/281/18
DiarrhoeaGastrointestinal disorders0/440/421/351/280/18
Lower gastrointestinal haemorrhageGastrointestinal disorders0/440/420/351/280/18
SepsisInfections and infestations0/440/420/351/280/18
Urinary tract infectionInfections and infestations0/440/420/351/280/18
Most frequent other events
Showing 10 of 94
Most frequent other events
EventDrug Cocktail - Period 1200 mg Abemaciclib - Period 2200 mg Abemaciclib + Drug Cocktail - Period 2200 mg Abemaciclib - Periods 3 and 4Abemaciclib Safety Extension Period
DiarrhoeaGastrointestinal disorders1/4418/4211/3512/282/18
Decreased appetiteMetabolism and nutrition disorders1/443/424/356/285/18
NauseaGastrointestinal disorders5/448/426/357/284/18
VomitingGastrointestinal disorders2/448/425/357/284/18
AnaemiaBlood and lymphatic system disorders0/441/422/356/282/18
FatigueGeneral disorders1/446/426/355/283/18
HypokalaemiaMetabolism and nutrition disorders0/445/420/355/283/18
Abdominal painGastrointestinal disorders2/446/422/352/283/18
ConstipationGastrointestinal disorders2/443/424/351/283/18
Urinary tract infectionInfections and infestations2/441/420/350/283/18

Baseline characteristics

All participants who received at least one dose of drug cocktail.

Age, Continuous
Age, Continuous(years)Overall
Mean60.1 ± 11.0
Sex: Female, Male
Sex: Female, Male(Participants)Overall
Female20
Male24
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Overall
Hispanic or Latino2
Not Hispanic or Latino41
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Overall
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American1
White40
More than one race0
Unknown or Not Reported2
Region of Enrollment
Region of Enrollment(Participants)Overall
United States44
08

Study locations

5 sites
  • Sarah Cannon Research Institute at HealthOne
    Denver, Colorado 80218, United States
  • IU Simon Cancer Center
    Indianapolis, Indiana 46202, United States
  • University of Kansas Hospital
    Fairway, Kansas 66160, United States
  • Mary Crowley Cancer Research Center
    Dallas, Texas 75230, United States
  • South Texas Accelerated Research Therapeutics, LCC
    San Antonio, Texas 78229-3307, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Feb 2018, 22 months.

Results were first posted in Oct 2022, 4 years 8 months after primary completion.

Of 287 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's 22 months is below that.

Counting every sponsor, half of 497 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2016
First posted
Feb 23, 2016
StartActual
Mar 8, 2016
Primary completionActual
Feb 4, 2018
CompletionActual
Jan 6, 2021
Results first posted
Oct 18, 2022
Last update
Oct 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02688088
Responsible party
Sponsor
First posted
Feb 23, 2016
Start date
Mar 8, 2016
Primary completion
Feb 4, 2018
Completion
Jan 6, 2021
Results posted
Oct 18, 2022
Last update
Oct 18, 2022

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Caffeine · Warfarin · Dextromethorphan · Midazolam · Omeprazole · Vitamin K 1 · Abemaciclib

Start the discussion